SharpyOzempic Price Cut 2027: New $675 List Price, Who Saves
Yes, the Ozempic price cut is real: on January 1, 2027, Novo Nordisk lowers the US list price of Ozempic, Wegovy and Rybelsus to $675 a month for every dose. That is about 35% off Ozempic and about 50% off Wegovy. It mostly helps people whose share is tied to list price, like those on high-deductible plans or coinsurance, while self-pay prices from NovoCare and TrumpRx do not change. Whatever you end up paying, Sharpy helps you get the most from each dose with a daily protein target and a 20-minute workout that protect muscle.
Is the Ozempic price cut real, and when does it start? Yes. On January 1, 2027, the US list price of Ozempic, Wegovy and Rybelsus drops to $675 a month, for every dose. Novo Nordisk says that is about 35% off Ozempic and about 50% off Wegovy. But the list price is not always what you pay. If you buy with cash through NovoCare or TrumpRx, your price does not change. The people who gain most are those on high-deductible or coinsurance plans.
Novo Nordisk first announced the cut on February 24, 2026. It is back in the news this week, with Medical Economics running it in its October 26 roundup, as open enrollment season puts 2027 drug costs on people's minds. Here is what changes, who saves and who does not.
What exactly is changing on January 1, 2027?
Novo Nordisk's press release lists the products and doses covered. Every dose of each is included.
| Medicine | Approved for | List price now (approx.) | List price from Jan 1, 2027 | Cut |
|---|---|---|---|---|
| Ozempic pen (0.25 mg to 2 mg) | Type 2 diabetes | About $1,000 a month | $675 a month | About 35% |
| Wegovy pen (up to 2.4 mg) | Weight management | About $1,350 a month | $675 a month | About 50% |
| Wegovy pill (oral semaglutide) | Weight management | Not reported | $675 a month | Not stated |
| Rybelsus tablets (7 mg, 14 mg) | Type 2 diabetes | About $1,000 a month | $675 a month | Not stated |
The "now" prices come from Axios's report on the announcement. Novo gave percentages, not old prices.
One thing to know: a list price (also called the wholesale acquisition cost) is the starting price Novo charges before rebates and discounts. Insurers, pharmacy benefit managers and pharmacies all work from it. That is why a list price cut helps some people a lot and others not at all.
Who will actually pay less after the Ozempic price cut?
Novo Nordisk said the goal is to help people whose costs are tied to the list price, naming "high-deductible health plans or co-insurance benefit designs." Here is how that plays out.
| How you pay | Will the cut lower your cost? | Why |
|---|---|---|
| Coinsurance (you pay a % of the price) | Likely yes | Your % is taken from a smaller number |
| High-deductible plan, before you meet the deductible | Likely yes | You pay closer to the full price until the deductible is met |
| Flat copay (like $25 or $50) | Probably not | Your copay is a fixed amount |
| Self-pay through NovoCare or TrumpRx | No | Novo says self-pay prices are not affected |
| Medicare Part D | Separate change | Medicare has its own negotiated price for 2027 |
| No coverage for the drug | Not directly | A lower list price does not make a plan cover it |
A simple example. Say your plan charges 25% coinsurance on the list price. On Wegovy at about $1,350, that is about $338 a month. At $675, it would be about $169. On Ozempic at about $1,000, 25% is $250; at $675 it is about $169. Real numbers vary, because plans often base your share on their own negotiated rate, not the exact list price. Call your plan and ask what your cost will be in 2027.
What about self-pay prices? Are they going down too?
No. Novo Nordisk said the list price change "does not impact" direct-to-patient, self-pay prices. Those were already far below list. When we checked TrumpRx.gov on October 21, 2026, the prices were:
| Self-pay option | Price |
|---|---|
| Ozempic, 0.25 mg to 1 mg | $349 a month |
| Ozempic, 2 mg | $499 a month |
| Wegovy pen, up to 2.4 mg | $349 a month ($399 at 7.2 mg) |
| Wegovy pill | $149 (1.5 mg) to $299 a month |
| New patients, first 2 fills of Wegovy or Ozempic at 0.25 or 0.5 mg | $199 a month (through Dec 31, 2026) |
So if you already pay cash, $349 is still well under the new $675 list price. For full details on each program, see our guides to TrumpRx GLP-1 prices and the Wegovy pill cost.
Paying less for the drug only helps if the weight you lose is mostly fat. Studies show a large share of weight lost on GLP-1s can come from lean mass, so protein and strength work matter. Sharpy sets one daily protein target, gives you one 20-minute workout and tracks a Shape Score, so you can see that the scale is moving for the right reason.
How does the Ozempic price cut fit with Medicare's 2027 price?
These are two separate things that both start in 2027.
- Medicare negotiation. Semaglutide (Ozempic, Wegovy, Rybelsus) was in the second round of Medicare drug price talks. CMS published the result in November 2025: a headline price of $274 a month, starting in Part D in 2027. Exact prices vary by product and strength.
- The list price cut. This applies across the market, mainly for commercial plans.
Medicare still has limits on covering drugs used only for weight loss. For what Medicare covers now, including the $50 a month GLP-1 Bridge, see our Medicare GLP-1 Bridge guide. Open enrollment for 2027 runs October 15 to December 7, 2026, so it is a good time to compare Part D plans.
Why is Novo Nordisk cutting the price?
Novo said patients and payers "have been calling for lower list prices," and that the change is meant to remove cost barriers. According to Axios, a Novo executive said this cut was not part of the company's November 2025 pricing deal with the White House. Competition is also heavy. Eli Lilly's Zepbound and its pill Foundayo are fighting for the same patients, and many employers are rethinking GLP-1 coverage for 2027, as we covered in insurance dropping GLP-1 coverage.
For how lower prices are already showing up in Novo's results, see our Wegovy sales 2026 guide to its November 2026 earnings report.
What should you do before January?
- Check your 2027 plan documents during open enrollment. Look at the drug list (formulary) for Ozempic or Wegovy, and whether you pay a copay or coinsurance.
- Ask your plan or HR how they will price the drug after January 1, 2027.
- Compare with self-pay. If your coverage is poor, cash at $349 may still beat your share.
- Do not stop or change doses to save money without talking to your prescriber. Stopping can bring the weight back.
- Keep records of what you pay. Our GLP-1 cost and coverage guide explains appeals and savings cards. For the current Ozempic Savings Card terms and self-pay prices, see our Ozempic coupon guide.
Remember that Ozempic is approved for type 2 diabetes. Wegovy is the semaglutide brand approved for weight management. Our Wegovy vs Ozempic guide explains the difference.
The bottom line
The Ozempic price cut lowers the list price of Ozempic, Wegovy and Rybelsus to $675 a month on January 1, 2027. It can cut real costs for people on coinsurance or high-deductible plans, but it does not change cash prices or force any plan to cover the drug. Check your 2027 plan now. And make each dose count: Sharpy helps you hit your protein target, train for 20 minutes a day and lose fat, not muscle.
Sources
- Novo Nordisk: Significant reduction in US list price for Wegovy, Ozempic and Rybelsus (PR Newswire via BioSpace, Feb 24, 2026)
- Axios: Novo Nordisk cuts sticker price of weight-loss drugs (Feb 24, 2026)
- HealthDay: Novo Nordisk cuts prices of Ozempic and Wegovy starting January 2027
- HLTH: CMS sets 2027 Medicare prices for Wegovy and other drugs (Nov 28, 2025)
- AMCP: CMS releases IPAY 2027 negotiated prices
- TrumpRx.gov
Questions people ask
Is Ozempic getting cheaper?
Yes, at the list price level. Novo Nordisk announced on February 24, 2026 that the list price (wholesale acquisition cost) of Ozempic, Wegovy and Rybelsus drops to $675 a month on January 1, 2027. Whether you pay less depends on how your plan works. People who pay a flat copay may see no change.
When will the Ozempic price drop?
The new $675 list price takes effect on January 1, 2027. Separately, Medicare's negotiated price for semaglutide also starts in 2027.
How much is Ozempic after the price cut?
The list price becomes $675 a month for all Ozempic doses (0.25 mg through 2 mg). Before the cut, Axios reported it at about $1,000 a month. Self-pay prices are separate: Ozempic is $349 a month at 0.25 to 1 mg and $499 at 2 mg through TrumpRx and NovoCare, and those do not change because of the list price cut.
Is the Wegovy price cut in half?
Close to it. Wegovy's list price falls about 50%, from about $1,350 a month to $675, according to Novo Nordisk and Axios. That covers the Wegovy pen and the Wegovy pill.
Does the price cut help people with insurance?
It helps most if your out-of-pocket cost is a percentage of the drug price (coinsurance) or if you pay the full price until you meet a deductible. Novo Nordisk named high-deductible and coinsurance plans as the target. If you pay a flat copay, your cost may stay the same. Your plan still decides whether it covers the drug at all.
Does the Ozempic price cut apply to Medicare?
The list price cut is a separate step from Medicare. Medicare has its own negotiated price for semaglutide that starts in 2027, reported at $274 a month as a headline figure, with exact prices varying by product. What you pay at the counter depends on your Part D plan.